Electronic Supplementary Information

Assemble Hepatitis E Vaccine by 'in situ' Growing Gold Clusters as Nano Adjuvant: An Efficient Way to Enhance the Immune Responses of Vaccination

Hai Wang^a, Yanping Ding^a, Shishuai Su^a, Duojia Meng^b, Ayeesha Mujeeb^a, Yan Wu^{a*}, Guangjun Nie^{a*}

^{*a*} CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), Beiyitiao, Zhongguancun, Beijing 100190, China.

^b Changchun Institute of Biological Products Co., ltd, 3456 Xian road, Changchun city, 130062, China.

*Correspondence should be addressed to: CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety National Center for Nanoscience and Technology (NCNST) Beiyitiao, Zhongguancun Beijing 100190, China Email: <u>niegj@nanoctr.cn</u> or wuy@nanoctr.cn




Fig. S1. UV/Vis absorbance of HEVA and HEVA/Au. Both HEVA and HEVA/Au have a major absorbance peak at 280 nm.




Figure S2. Circular dichroism (CD) spectroscopy of HEVA and HEVA/Au, showing the Au cluster didn't change the secondary structure of the vaccine.




Figure S3. Surface zeta potential of HEVA and HEVA/Au showing the Au cluster have no effects on the surface charge of the vaccine. The zeta potential was determined by DLS.




Figure S4. *Ex vivo* imaging of different organs from mouse treated with HEVA/Au after injection for 6 h. Excitation wavelength, 350 nm; Emission wavelength, 450 nm. This image showed the *in vivo* imaging capability of HAVA/Au, which can be used for the monitoring of the biodistribution of vaccine.




Figure S5. *In vitro* cell viability of HepG2 cells (a) and iDC cells (b) after incubating with low concentrations of both HEVA and HEVA/Au for 24h. The cell viability was determined by CCK-8 assay.